Dyne therapeutics investors
WebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised to date? Dyne Therapeutics has raised $333M. When was the last funding round for Dyne Therapeutics? Dyne Therapeutics closed its last funding round on Jan 21, 2024 from a … WebMar 20, 2024 · However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release. Contacts: Investors Dyne Therapeutics …
Dyne therapeutics investors
Did you know?
WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... Web10 rows · Dyne Therapeutics has raised a total of $333M in funding over 4 rounds. Their latest funding was ...
WebAug 10, 2024 · Dyne Therapeutics today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital. Contacts Stephanie Simon Ten Bridge Communications (617 ... WebApr 11, 2024 · Finally, Tower Research Capital LLC TRC boosted its stake in Dyne Therapeutics by 425.0% in the third quarter. Tower Research Capital LLC TRC now owns 9,582 shares of the company's stock valued at $122,000 after buying an additional 7,757 shares in the last quarter. Institutional investors own 85.50% of the company's stock. …
WebDyne Therapeutics General Information. Description. Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically … WebDyne Therapeutics to Present at Upcoming Investor Conferences. WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a …
WebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The …
WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... Investors Dyne ... bsbwhs417 answersWebApr 13, 2024 · Aurinia Pharmaceuticals Inc (AUPH) stock is trading at $11.20 as of 3:06 PM on Thursday, Apr 13, a rise of $0.16, or 1.5% from the previous closing price of $11.03. The stock has traded between $11.04 and $11.49 so far today. Volume today is less active than usual. So far 1,641,446 shares have traded compared to average volume of 3,314,036 … bsbwhs417WebNov 3, 2024 · WALTHAM, Mass., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2024 and business … excel shortcut for adding $WebMar 2, 2024 · Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights. March 2, 2024 . PDF Version ... Investors Amy Reilly … bsbwhs515WebMar 20, 2024 · About Dyne Therapeutics. ... Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 . bsbwhs505 investigate whs incidentsWebNX-13. NX-13 is an oral NLRX1 agonist for the treatment of Ulcerative Colitis and Crohn’s Disease. NX-13’s bimodal mechanism of action aims to decrease reactive oxygen … excel shortcut fixed cellWebMar 23, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203 Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 … excel shortcut for adjusting cell width